An interventional study of MagnetOs Easypack Putty and Demineralized Bone Matrix or Fibers mixed with local autograft bone in Degenerative Disc Disease, Spine Fusion and Back Pain, sponsored by Kuros Biosurgery AG. Active, not recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Kuros Biosurgery AG · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 232 studies in Intervertebral Disc Degeneration with a site in United States — 41 open to participants now, 58 under way, 5 of them phase 3. Intervertebral Disc Degeneration · United States.
Among the 232 studies in Intervertebral Disc Degeneration with a site in United States, this one is the 64th largest by planned enrollment of the 141 interventional ones that give a count, is one of 10 that started in 2024, is one of 90 with no phase, reaches primary completion later than 39 of the 57 other live ones, and was the 171st registered.
462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.
Browse Intervertebral Disc Degeneration studies →41 of the 232 studies in Intervertebral Disc Degeneration with a site in United States are open now. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 18+
CGBio Inc. · Sites in United States
Ages 21–80
EicOsis Human Health Inc. · Sites in United States
Ages 18+
DiscGenics, Inc. · Sites in United States
Ages 18–75
VIVEX Biologics, Inc. · Sites in United States
Ages 22–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
232 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 20 · Phase 3 18 · Phase 4 8
First in 1998; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 60 across 256 interventional studies indexed under Intervertebral Disc Degeneration.
Median enrollment 57 across the 141 interventional studies, 118 across the 91 observational. Of the 132 that completed or were terminated, 44 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
165 of 232 have an industry lead sponsor. The 10 most frequent:
Kuros Biosurgery AG is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Kuros Biosurgery AG has 5 studies filed under Intervertebral Disc Degeneration — fewer than ten, so there is no comparison to draw.
17 of the studies in Intervertebral Disc Degeneration with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06325566Phase 3Mesoblast, Ltd.Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain | 2027-07 |
| NCT07254806Phase 3DiscGenics, Inc.A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease | 2027-11-24 |
| NCT05740176Synergy Spine SolutionsThe Synergy Disc for the Treatment of 2 Level Cervical Degenerative Disc Disease Compared With Cervical Fusion Surgery | 2026-11 |
| NCT05037968Kuros Biosurgery AGMagnetOs Flex Matrix Compared to Trinity Elite Mixed With Local Autograft in Patients Undergoing up to Four-level Instrumented Posterolateral Fusion | 2026-12 |
| NCT04388332Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)ACDF Using Structural Allograft vs. Tritanium C | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 232 studies in Intervertebral Disc Degeneration with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase IV post-marketing study for MagnetOs Easypack Putty. MagnetOs Easypack Putty is a synthetic bone graft extender product that is routinely used by surgeons as a treatment for patients with degenerative disc disease or spinal trauma undergoing spinal fusion surgery.
In this study, MagnetOs Easypack Putty will be used according to the latest U.S. Instructions For Use, standalone in the posterolateral spine.
In this study, following a screening period of a maximum of 30 days, 60 patients will undergo up to two-level instrumented posterolateral fusion (PLF) procedure. Prior to surgery, each patient will be randomized to receive MagnetOs Easypack Putty standalone on the assigned side of the spine and Demineralized Bone Matrix or Fibers mixed with local autograft bone on the other at the diseased levels. They will be followed up at discharge, Week 2, Month 3, Month 6, and Month 12. An interim analysis will be performed once 30 patients have completed their Month 6 visit and have measurements for the endpoints available to measure effectiveness. The primary endpoint will be analyzed at Month 12.
In this study, MagnetOs Easypack Putty will be applied according to the latest Instructions for Use approved in the United States. Specifically, MagnetOs Easypack Putty will be used standalone in patients up to two-level degenerative disc disease with segmental mechanical spinal instability requiring treatment with an instrumented posterolateral spine fusion procedure. The fusion procedure (PLF) will be left to the surgeon's discretion.
Radiographs will be obtained at Screening, Discharge, Month 3, Month 6 and Month 12. CT scans will only be obtained at Month 6 and Month 12.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Instability can be either caused by degenerative disc disease or by traumatic injury to the spinal column. Patient requiring a maximum of two-level instrumented posterolateral lumbar/thoraco-lumbar fusion (T11 - S1) will be enrolled. Mechanical instability is defined by the presence of one or more of the following:
Unstable burst fracture
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Interventions * Procedure: Instrumented posterolateral spine fusion * Device; MagnetOs Easypack Putty
Device: MagnetOs Easypack Putty
Interventions * Procedure: Instrumented posterolateral spine fusion * Device: Demineralized Bone Matrix or Fibers mixed with local autograft bone
Device: Demineralized Bone Matrix or Fibers mixed with local autograft bone
MagnetOs Easypack Putty used standalone in instrumented posterolateral fusion, 5cc-15c per spine level at the randomized assigned side.
Demineralized Bone Matrix or Fibers (DBX or Grafton) mixed in a 1:1 vol% with local autologous bone graft used in instrumented posterolateral fusion, 5cc-15cc per level mixed with bone marrow aspirate/blood per spine level at the contralateral side.
Radiographic Fusion by CT Scan
The rate of posterolateral lumbar/thoracolumbar fusion assessed by CT-scan at Month 12. Radiographic as determined by evidence of bridging trabeculae or continuous bony connection between the superior and inferior transverse processes.
Time frame: Month 12
Radiographic Fusion by Plain Radiographs
The rate of posterolateral lumbar/thoracolumbar fusion assessed by plain radiographs.
Time frame: Month 6, Month 12
Radiographic Fusion by CT Scan
The rate of posterolateral lumbar/thoracolumbar fusion assessed by CT-scan at Month 6. Radiographic as determined by evidence of bridging trabeculae or continuous bony connection between the superior and inferior transverse processes.
Time frame: Month 6
Functional Outcome by Oswestry Disability Index Questionnaire
Functional outcome by the Oswestry Disability Index questionnaire. Patient-completed questionnaire which gives a subjective percentage score of level of function (disability) in activities of daily living in those rehabilitating from low back pain. The lower the percentage the higher the patient's functionality. 0-20% minimal disability, 80-100% significant disability or bedridden.
Time frame: Screening, Week 2, Month 3, 6, and 12
Back and Leg Pain by Visual Analog Pain Scale Questionnaire
Change in back and leg pain using Visual Analog Pain Scale (0-100). Patient-completed questionnaire scoring pain by using 100 mm line. Zero being no pain, 100 is worst pain imaginable.
Time frame: Screening, Week 2, Month 3, 6, and 12
Neurologic Status by Physical Exam
Change in neurologic status by examination to document stable, improved, or deficits in condition. Stable or improved findings for lower extremities, specifically reflexes, muscle strength, sensory, and straight leg raise.
Time frame: Screening, Week 2, Month 3, 6, and 12
Success Rate
Number of patients with secondary surgical interventions (SSI's) such as revisions, re-operations, removals, supplemental fixations, or any other procedure that adjusts or removes part of the original implant configuration with or without replacement of the components within 12 months of surgery.
Time frame: Week 2, Month 3, 6, and 12
Safety Endpoint - number of patients with Adverse Events
The number of patients with Adverse Events from Screening up to Month 12 after surgery.
Time frame: 12 Months
Safety Endpoint - number of patients with Serious Adverse Events
The number of patients with Serious Adverse Events from Screening up to Month 12 after surgery
Time frame: 12 Months
Safety Endpoint - number of patients with Adverse Device Effects
The number of patients with Adverse Device Effects from Screening up to Month 12 after surgery.
Time frame: 12 Months
Safety Endpoint - number of patients with Device Related Complications
The number of patients with any complications considered to device related with 12 months after surgery.
Time frame: 12 Months
Health Economic - Duration of Surgery
Duration of surgery in minutes.
Time frame: 12 Months
Health Economic - Duration of Hospitalization
Duration of hospital stay in days.
Time frame: 12 Months
Health Economic - Return to Work
Time to return to work in days.
Time frame: 12 Months
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 35 months after the start.
Of 45 industry-sponsored interventional studies with no phase under Intervertebral Disc Degeneration, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 82. This study's planned 35 months is below that.
Counting every sponsor, half of 85 studies reached it within 50 months; a quarter within 27 and three quarters within 72.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Jun 2027 → Dec 2027 and completion Aug 2027 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intervertebral Disc Degeneration →
Kuros Biosurgery AG